Glucocorticoid treatment in patients with septic shock: Effects on vasopressor use and mortality

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 7, 2006, Pages 309-318

  Boyer, A ^a   Chadda, K ^b   Salah, A ^c   Annane, Djillali ^c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Glucocorticoids; Hydrocortisone; Meta analysis; Mortality; Septic shock

Indexed keywords

AUTACOID; CATECHOLAMINE; CORTICOSTEROID; CORTICOTROPIN; ENDOTOXIN; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYPERTENSIVE AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; NORADRENALIN; PLACEBO; TRANSCRIPTION FACTOR AP 1;

ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR RESPONSE; CELL MIGRATION; CLINICAL TRIAL; CORTICOTROPIN TEST; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; GASTROINTESTINAL HEMORRHAGE; GENETIC TRANSCRIPTION; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPOTENSION; INFLAMMATORY CELL; LOW DRUG DOSE; MEDICAL ASSESSMENT; META ANALYSIS; MORTALITY; NONHUMAN; RAT; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SKIN TEST; SUPERINFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASOCONSTRICTION; VOLUNTEER;

EID: 33745921199     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44309     Document Type: Article

References (79)

1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996; 383: 787-793.
2. Annane D, Belissant E, Sebille V, Lesieur V, Lesieur O, Mathieu B, Raphael JC, Gajdos P. Impaired pressor sensitivity to noradrenalin in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol. 1998; 46: 589-597.
3. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000; 283: 1038-1045.
4. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288: 862-871.
5. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004; 329: 480.
6. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005; 365: 63-78.
7. Artz E, Sauer J, Pollmacher T, Labeur M, Holsboer F, Reul JM, Stalla GK. Glucocorticoids suppress interleukin-1 receptor antagonist synthesis following induction by endotoxin. Endocrinology. 1994; 134: 672-677.
8. Beato M. Gene regulation by steroid hormones. Cell. 1989; 56: 335-344.
9. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med. 2001; 27.: 1584-1591.
10. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine: mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther. 2000; 68: 293-303.
11. Bhagat K, Collier J, Vallance P. Local venous responses to endotoxin in humans. Circulation. 1996; 94: 490-497.
12. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiological doses of hydrocortisone. Crit Care Med. 1998; 26: 645-650.
13. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987; 317: 653-658.
14. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993; 119: 1198-1208.
15. Briegel J, Forst H, Hellinger H, Haller M. Contribution of cortisol deficiency to septic shock. Lancet 1991; 338: 507-508.
16. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Humel T, Lenahart A, Heyduck M, Stoll C, Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock. Crit Care Med. 1999; 27: 723-732.
17. Catalano RD, Parameswaran V, Ramachandran J, Trunkey DD. Mechanisms of adrenocortical depression during Escherichia coli shock. Arch Surg. 1984; 119: 145-150.
18. Chawla K, Kupfer Y, Goldman I, Tessler S. Hydrocortisone reverses refractory septic shock. Crit Care Med. 1999; 27: 33A.
19. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005; 171: 242-248.
20. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the anti-inflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intracellular adhesion molecule 1. Proc Natl Acad Sci USA. 1992; 89: 9991-9995.
21. Dailey JW, Westfall TC. Effects of adrenelectomy and adrenal steroids on norepinephrine synthesis and monoamine oxidase activity. Eur J Pharmacol. 1978; 48: 383-391.
22. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock. 1998; 9: 1-11.
23. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-biphosphate. Science. 1997; 275: 665-668.
24. Giorgino F, Pedrini MT, Matera L, Smith RJ. Specific increases in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J Biol Chem. 1997; 272: 7455-7463.
25. Gonzalez-Hernandez JA, Ehrhart-Bornstein M, Spathsch-Walbe E, Sherbaum WA, Bornstein SR. Human adrenal cells express tumor necrosis factor-α messenger ribonucleic acid-evidence for paracrine control of adrenal function. J Clin Endocrinol Metab. 1996; 81: 807-813.
26. Grunfeld JP, Eloy L. Glucocorticoid modulates vascular reactivity in the rat. Hypertension. 1987; 10: 608-618.
27. Guha M, Mackman N. The phosphatidyl 3-kinase-Akt pathway limits lipopolysaccharide activation of signalling pathway and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002; 277: 32124-32132.
28. Hahn EO, Houser HB, Rammelkamp CH Jr, Denny FW, Wannamaker LW. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. J Clin Invest. 1951; 30: 274-281.
29. 1-adrenergic receptor binding in rat vascular smooth muscle. J Mol Endocrinol. 1990; 5: 41-48.
30. Hinshaw LB. Design and conduct of clinical trials: development of a clinical study based on animal data. In: Bond F, Adams HR, Chaudry IS (eds). Perspectives in shock research. New York: Alan R Liss; 1988. pp 51-60.
31. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol Today. 1990; 11: 443-449.
32. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, KLender P, Xanthoukadis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol. 2000; 1: 496-501.
33. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001; 166: 6952-6963.
34. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348: 138-150.
35. Huang ZH, Gao H, Xu RB. Study on glucocorticoid receptors during intestinal ischemia and septic shock. Circ Shock. 1987; 23: 27-36.
36. Hugues GS Jr. Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Life Sci. 1984; 35: 2319-2326.
37. Keh D, Boehnke T, Weber-Cartens S, Schultz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H. Immunologic and hemodynamic effects of "low dose" hydrocortisone in septic shock. Am J Resp Crit Care Med. 2003; 167: 512-520.
38. Kennedy B, Ziegler MG. Cardiac epinephrine synthesis. Regulation by a glucocorticoid. Circulation. 1991; 84: 891-895.
39. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections. N Engl J Med. 1971; 284: 1248-1250.
40. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995; 23: 1294-1303.
41. Lenczowski MJ, Schmidt ED, Van Dam AM, Gaykema RP, Tilders FJ. Individual variations in hypothalamus-pituitary-adrenal responsiveness of rats to endotoxin and interleukin-1 beta. Ann NY Acad Sci. 1998; 856: 139-147.
42. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg. 1984; 119: 537-541.
43. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988; 138: 62-68.
44. Maxime V, Chadda K, Orlikowski D, Bessereau J, Colin G, Ratrimoson T, Rigal G, Tcherakian C, Clair B, Raphael JC, Gajdos P, Annane D. Corticoresistance périphérique au cours du sepsis. Réanimation 2003; 11 (Abstract): 67S.
45. McCann SM, Karanth S, Kamat A, Lee Dees W, Lyson K, Gimeno M, Rettori V. Induction by cytokines of the pattern of pituitary hormone secretion in infection. Neuroimmunomodulation. 1994; 1: 2-13.
46. McKenzie AW, Stoughton RB. Methods of comparing percutaneous absorption of steroids. Arch Derm. 1962; 86: 606-610.
47. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoid on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996; 156: 4422-4428.
48. Meibohm B, Derendorf H, Mollmann H, Frohlich P, Tromm A, Wagner M, Homrighausen S, Krieg M, Hochhaus G. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther. 1999; 37: 367-376.
49. Molijn GJ, Spek JJ, Van Uffelen JC, de Jong FH, Brickmann AO, Bruining HA, Lamberts SW, Kopper JW. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrin Metabol. 1995; 80: 1799-1803.
50. Oppert M, Schindler R, Husung C, Offerman K, Gräf KJ, Boenisch O, Barckow D, Frei R, Eckardt KU. Low dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005; 33: 2457-2464.
51. Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT. Negative transcriptional regulation of human interleukin-2 gene by glucocorticoid through interference with nuclear transcriptional factors AP-1 and NF-AT. J Clin Invest. 1993; 91: 1481-1489.
52. Pathan K, Raymond JR, Singh I. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxyde synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J Biol Chem. 1999; 274: 7528-7536.
53. Paya D, Gray GA, Fleming I, Stoclet JC. Effect of dexamethasone on the onset and persistence of vascular hyporeactivity induced by E. coli lipopolysaccharide in rats. Circ Shock. 1993; 41: 103-112.
54. Perrot D, Bonneton A, Dechaud H, Motin J, Pugeat M. Hypercortisolism in septic shock is not suppressible by dexamethasone infusion. Crit Care Med. 1993; 21: 396-401.
55. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcriptional factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA. 1994; 91: 752-756.
56. Rogers J. Large doses of steroids in septicaemic shock. Br J Urol. 1970; 42: 742A.
57. Rook G, Baker R, Walker B, Honour J, Jessop D, Hernandez-Pando R, Arriaga K, Shaw R, Zumla A, Lightman S. Local regulation of glucocorticoid activity in sites of inflammation. Insights from the study of tuberculosis. Ann NY Acad Sci. 2000; 917: 913-922.
58. Rothwell PW, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991; 337: 582-583.
59. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the α1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest. 1991; 88: 385-389.
60. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994; 23: 25-30.
61. Schneider AJ, Voerman HJ. Abrupt hemodynamic improvement in late septic shock with physiological doses of glucocorticoids. Intensive Care Med. 1991; 17: 436-437.
62. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976; 184: 333-339.
63. Sharshar T, Gray F, Lorin de la Grandmaison G, Hopkinson NS, Ross E, Dorandeu A, Orlikowski D, Raphael JC, Gajdos P, Annane D. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet. 2003; 362: 1799-1805.
64. Skundric DS, Bealmear B, Lisak RP. Induced up regulation IL-1, IL-1ra and IL-1R type 1 gene expression by Schwann cells. J Neuroimmunol. 1997; 74: 9-18.
65. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M. The effect of high-dose corticosteroids in patients with septic shock. N Engl J Med. 1984; 311: 1137-1143.
66. Steiner A, Vogt E, Locher R, Vetter W. Stimulation of the phosphoinositide signalling system as a possible mechanism for glucocorticoid action in blood pressure control. J Hypertens. 1988; 6: S366-S368.
67. O'Sullivan ST, Lederer JA, Horgan AF, Chin DHL, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995; 222: 482-492.
68. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of sepsis. N Engl J Med. 1987; 317: 659-665.
69. Thiemermann C, Vane JR. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol. 1990; 182: 591-595.
70. Thomas L. Germs. N Engl J Med. 1972; 287: 553-555.
71. Thomas KW, Monick MM, Stabler JM, Yarovinsky T, Carter AB, Hunninghake GW. Respiratory syncitial virus inhibits apoptosis and induces N-Kappa B activity through a phosphatidylinositol 3-kinase dependent pathway. J Biol Chem. 2002; 277: 492-501.
72. Thompson WL, Gurley HT, Lutz BA, Jackson DL, Kvols LK, Morris IA. Inefficacy of glucocorticoids in shock (double-blind study). Clin Res. 1976; 24: 258A.
73. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroids/thyroid receptor superfamily members. Annu Rev Biochem. 1994; 63: 889-895.
74. Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G. Reducing mortality in sepsis: new directions. Crit Care Med. 2002; 6 (Suppl 3): S1-S18.
75. Williamson PM, Kohlhagen JL, Mangos GJ et al. Acute effects of hydrocortisone on plasma nitrate/nitrite activity and forearm vasodilator responsiveness in normal human subjects. Clin Exp Pharmacol Physiol. 2005; 32: 162-166.
76. Wong ML, Rettori V, al-Shecklee A, Bongiorno PB, Canteros G, McCann SM, Gold PW, Licinio J. Inductible nitric oxide synthase gene expression in the brain during systemic inflammation. Nat Med. 1996; 2: 581-584.
77. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-556.
78. Yard AC, Kadowitz PJ. Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur J Pharmacol. 1972; 20: 1-9.
79. Zubiaga AM, Munoz E, Huber BT. IL-4 and IL-2 selectively rescue Th cells subsets from glucocorticoid-induced apoptosis. J Immunol. 1992; 149: 107-112.